Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Melanoma, Cutaneous Malignant × relatlimab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 7 Carcinoma, Non-Small-Cell Lung 3 Squamous Cell Carcinoma of Head and Neck 2 Neoplasms 2 Carcinoma, Basal Cell 2 Urologic Neoplasms 1 Urogenital Neoplasms 1 Urogenital Diseases 1 Urinary Bladder Neoplasms 1 Urinary Bladder Diseases 1 Neoplasms by Site 1 Nasopharyngeal Carcinoma 1 Muscle Invasive Bladder Urothelial Carcinoma 1 Melanoma, Cutaneous Malignant 1 Male Urogenital Diseases 1 Locally Advanced Melanoma 1 Female Urogenital Diseases and Pregnancy Complications 1 Female Urogenital Diseases 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1

Interventions

relatlimab 1 pembrolizumab 1 lifileucel 1 Temozolomide 1 Paclitaxel 1 Opdualag 1 Nivolumab 1 Ipilimumab 1 Eye Movement Desensitization Reprocessing 1 Dacarbazine 1 Carboplatin 1 Albumin-Bound Paclitaxel 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06743126 2026-04-13

SUPRAME

Immatics US, Inc.

Phase 3 Recruiting

Melanoma, Cutaneous Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡